FDI-6 and Olaparib Synergistically Inhibit the Growth of Pancreatic Cancer by Repressing BUB1, BRCA1 and CDC25A Signaling Pathways.
Sign Up to like & getrecommendations! Published in 2021 at "Pharmacological research"
DOI: 10.1016/j.phrs.2021.106040
Abstract: Inducing homologous recombination (HR) deficiency is a promising strategy to broaden the indication of PARP1/2 inhibitors in pancreatic cancer treatment. In addition to inhibition kinases, repression of the transcriptional function of FOXM1 has been reported… read more here.
Keywords: olaparib synergistically; brca1; cdc25a; pancreatic cancer ... See more keywords